EFL Oral Production via Feedback： Focus on Form vs. Focus on Meaning
胃食管反流 英语
胃食管反流英语Gastroesophageal reflux disease (GERD) is a common digestive condition that affects millions of people worldwide. It occurs when the contents of the stomach, including acid and food, flow backward into the esophagus, the tube that connects the mouth to the stomach. This backward flow, known as reflux, can cause a range of uncomfortable symptoms, including heartburn, chest pain, and regurgitation.The primary cause of GERD is a weakness in the lower esophageal sphincter (LES), a muscle that acts as a valve between the esophagus and the stomach. When the LES relaxes abnormally or weakens, it allows stomach contents to flow back into the esophagus. Other contributing factors include overproduction of stomach acid, hiatal hernia, obesity, smoking, and certain foods and beverages that can trigger reflux.Symptoms of GERD can vary from person to person, but the most common include heartburn, a burning sensation behind the breastbone that often occurs after eating or lying down, and regurgitation, which is the feeling of foodor liquid coming back up into the mouth. Less common symptoms may include chest pain, difficulty swallowing, and a persistent dry cough.Diagnosing GERD typically involves a thorough medical history and physical examination, along with tests such as endoscopy, which allows doctors to visually inspect the esophagus and stomach. Other tests may include pH monitoring, which measures the acidity of esophageal contents, and esophageal manometry, which assesses the function of the LES.Management of GERD typically involves lifestyle modifications and medical therapy. Lifestyle changes may include avoiding trigger foods and beverages, losing weight, smoking cessation, and elevating the head of the bed to reduce reflux at night. Medical therapy may include over-the-counter or prescription medications such as antacids, histamine2-receptor antagonists, and proton pump inhibitors, which help neutralize stomach acid or reduce acid production.In severe cases or when symptoms do not respond to lifestyle changes and medication, surgical options may beconsidered. Surgical procedures such as laparoscopic fundoplication, which tightens the LES, and endoscopic procedures, which aim to improve the function of the LES, may be performed.In conclusion, gastroesophageal reflux disease is a common condition that can significantly impact a person's quality of life. Understanding its causes, symptoms, and management options is essential for effective treatment. With the help of lifestyle modifications and medical therapy, most people with GERD can achieve symptom relief and avoid the progression of the disease.**胃食管反流病：对其成因、症状与管理的深入洞察** 胃食管反流病（GERD）是一种常见的消化系统疾病，影响着全球数百万人。
生长激素联合低热量营养支持对外科术后氮平衡和血糖的影响
生长激素联合低热量营养支持对外科术后氮平衡和血糖的影响张明鸣1，伍晓汀1，郑亚民2，周勇1，钱昆11四川大学华西医院普外科，四川成都（610041）2首都医科大学宣武医院普外科，北京（100053）E-mail：wawjwj_100@摘要：目的观察生长激素（rhGH）联合低热量营养在外科择期术后病人治疗中的营养支持效果和对血糖的影响。
方法将48例择期术后病人随机分为rhGH组和对照组，两组治疗和营养支持方案相同，rhGH组于术后第3～9 d给予rhGH。
在术前1 d，术后3 d、10 d 分别测定体重、血常规、肝肾功能、血浆蛋白指标，检测每日氮平衡，同时记录每日血糖水平、胰岛素用量、并发症及不良反应。
结果术后第10 d，rhGH组累积氮平衡和血浆纤维连接蛋白水平优于对照组（p＜0.05）；术后第4 d和6～9 d，rhGH组每日氮平衡均优于对照组（p＜0.05）；rhGH组治疗期间血糖水平升高，但程度较轻，可为胰岛素有效控制，未观察到严重并发症发生。
结论rhGH联合低热量营养支持可以安全地促进蛋白合成、维持正氮平衡，改善营养状况和预后。
关键词：生长激素；营养支持；高血糖中图分类号： R459.3外科创伤后营养支持不但需要给予足够的营养底物补充消耗，还应添加特殊营养素，提供代谢支持，促进营养底物利用，降低分解代谢，加速组织修复[1]。
我们采用生长激素（rhGH）联合低热量营养支持，观察对外科术后蛋白合成、氮平衡和血糖水平的影响，以及可能出现的不良事件，进一步探讨联合营养治疗的有效性和安全性。
1．资料与方法1．1 临床资料接受胃肠道外科中等以上手术的成年病人48例，根据随机分配表将受试者随机分为研通讯作者：伍晓汀，电子邮箱：wawjwj_100@究组或对照组。
研究组24例，男15例，女9例，年龄35～74（59.08±10.93）岁，身高（162.88±7.16）cm，体重（56.19±11.83）kg；其中胃手术5例，结肠手术7例，直肠手术9例，其它部位手术3例。
发酵法生产1,3-丙二醇的研究进展
2017年第36卷第4期 CHEMICAL INDUSTRY AND ENGINEERING PROGRESS·1395·化 工 进展发酵法生产1,3-丙二醇的研究进展李晓姝，张霖，高大成，师文静，樊亚超（中国石油化工股份有限公司抚顺石油化工研究院，辽宁 抚顺113001）摘要：1,3-丙二醇是一种重要的化合物，近年来由于其用途的不断拓宽而越来越受到广泛重视。
生物合成法生产1,3-丙二醇具有绿色高效、使用可再生能源等特点，是目前最具前景的生产方式。
本文从发酵菌种、发酵工艺、发酵过程优化和精制提纯几个方面对发酵法生产1,3-丙二醇的研究现状进行了介绍。
提出为使生物法生产1,3-丙二醇在成本上与化学法相比更具优势，在提高产量的同时应该引入新技术、新手段对发酵过程进行强化，使得过程更加精准且易于控制；同时指出综合考虑经济性与能耗问题，对发酵与分离的全过程进行整合，是今后发酵法生产1,3-丙二醇实现产业化的研究重点。
关键词：1,3-丙二醇；发酵；生物转化；甘油中图分类号：TQ 923 文献标志码：A 文章编号：1000–6613（2017）04–1395–09 DOI ：10.16085/j.issn.1000-6613.2017.04.032Progress on the production of 1,3-propanediol by fermentationLI Xiaoshu ，ZHANG Lin ，GAO Dacheng ，SHI Wenjing ，F AN Yachao（Fushun Research Institute of Petroleum and Petrochemicals ，SINOPEC ，Fushun 113001，Liaoning ，China ）Abstract ：1,3-propanediol is an important chemical compound ，which has recently received more andmore attention due to its wide applications. Synthesizing 1,3-propanediol via the biological method has some merits ，such as green ，high efficiency ，and sustainable. This method is the most promising for the 1,3-propanediol production.In this paper ，the research advances on production of 1,3-propanediol by fermentation were reviewed with regard to fermentative strains ，fermentation process ，process optimization and purification. To have a low cost advantage over the other chemical synthesizes ，the biological method needs to increase the concentration of 1,3-propanediol ，to strengthen the fermentation process that is more accurate and easier control. Economy and energy consumption need to be considered to integrate the whole process of fermentation and separation ，which should be the focus of research and industrial production of 1,3-propanediol by biological process in the future. Key words ：1,3-propanediol ；fermentation ；bioconversion ；glycerol1,3-丙二醇（1,3-PD ）是一种重要且用途广泛的化工原料，其与对苯二甲酸聚合合成的聚对苯二甲酸丙二醇酯（PTT ），是一种性质优良的聚酯材料。
药英单词总结
Paralysis n . 麻痹，无力停顿Stroke n .中风，打击Congestive heart failure CHF 充血性心力衰竭Cardiomyopathy n .心肌症Ipecac syrup 吐根糖浆Spastic dysphonia 痉挛性发音困难，声带痉挛Botox 肉毒杆菌，肉毒杆菌毒素M.R.I.(magnetic resonance imaging) 核共振成像Phenytoin sodium 苯妥英钠IV intravenous injection 静脉注射IG immune globulin 免疫球蛋白Small cell lung cancer SCLC 小细胞肺癌Lambert-Eaton syndrome 兰伯特-伊顿综合征Thymus gland 胸腺Digeorge syndrome 迪格奥尔格综合征Porphyrin 卟啉Acute intermittent porphyria AIP 急性间歇性卟啉病Methanol 甲醇Ethanol 乙醇Pheochromocytoma 嗜络细胞瘤Chromaffin cell 嗜络细胞TIA暂时性脑缺血发作Anti-biotic 抗生素TB tuberculosis 结核病PPD purified protein derivative 纯蛋白衍生物ECG，EKG 心电图Sick sinus syndrome 病态窦房结综合征Cardiac arrest 心脏停搏Sinus 窦Nasal spay 鼻腔喷雾器Antihistamine 抗组胺药Steroids 类固醇Fever 发烧Diarrhea 腹泻Flu 流感Lump 肿块Optimum 良性Malignant 恶性False-positive 假阳性Negative 阴性Biopsy 活检Pink eye 红眼病Levofloxacin左氧氟沙星Streptomycin 链霉素Isoniazid 异烟肼（rimifom 雷米封）Tumor 癌Autonomic nerve system 自律神经Fentanyl 芬太尼（止痛剂）Morphine 吗啡Transfusion 输液Cerebrospinal fluid 脑脊液Dysentery 痢疾Dengi fever 登革热Staph , staphylococci 葡萄球菌Insulin 胰岛素Pancreas 胰腺Rash 皮疹Tick 扁虱Euphoria 精神愉快，欣快，欣快感Legionella 军团菌Brain biopsy 大脑活检Parasite 寄生虫Naegleria 耐格里原虫Amebic parasite 阿米巴原虫Primary amoebic meningoence phalitis 原发性阿米巴脑膜炎PAM Inflame 发炎Rickets 佝偻病Scurvy 坏血病Thiamin 维生素B1Assimilate 吸收，消化Contract 得（病）Dentistry 牙科Ethylene 乙烯，亚乙基Insensitive 感觉迟钝的，不敏感的Ghastly 可怕的，恐怖的，死人般的Inhalation 吸入（药剂）Irritant 刺激物Nauseate 使恶心。
每周只需注射一次,3个月即可轻松减掉10斤肥肉能让你管住嘴的减肥神药真的来了 临床大发现
每周只需注射一次，3个月即可轻松减掉10斤肥肉。
能让你管住嘴的减肥神药真的来了临床大发现“管住嘴，迈开腿”简简单单六个字，就道出了减肥的真谛。
然而，面对那么多的美食诱惑，光这前三个字就足以让无数人的减肥大业半途而废了。
不过，好消息来了！最近，肥胖研究领域中的著名期刊《糖尿病，肥胖和代谢》杂志刊登的一项临床研究[1]显示，诺和诺德公司开发的索马鲁肽，可以抑制食欲，让你轻松“管住嘴”。
只需一周注射1次，连续注射12周后，就可减重10斤！而且，在这减轻的体重中，主要还是体内的脂肪组织，药物对除脂肪以外的去脂体重影响很小。
不光有效，还很安全！这项研究的通讯作者，来自英国利兹大学的John Blundell 教授表示，“索马鲁肽的作用是非常令人惊讶的，我们在12周内就观察到了其他减肥药物需要6个月才能达到的效果。
它减少了饥饿感和食欲，让患者能更好地控制饮食摄入。
”[2] John Blundell教授索马鲁肽（Semaglutide）本身是一款针对2型糖尿病的降糖药，主要成分为胰高血糖素样肽-1（GLP-1）类似物。
GLP-1是一种由小肠分泌的激素，在血液中葡萄糖水平升高时促进胰岛素的合成和分泌。
GLP-1进入人体后很容易被酶降解，天然的GLP-1半衰期仅有几分钟，所以，为了让它更长久的工作，研究人员会对它进行一些结构上的改造，在保留功能的同时不那么容易被酶降解。
这样得到的GLP-1类似物药物，比如大名鼎鼎的利拉鲁肽，可以将注射频率减缓到每天1~2次。
而索马鲁肽可以说是它们的“升级版”，在经过改造后，它的半衰期可延长至大约1周，因此注射一次的效果可以维持大约一周的时间[3]，对于患者来说更方便。
在不久前公布的全球大型III期临床试验中，索马鲁肽表现优秀，既能控制血糖，还可以保护心血管，这为它在上周赢得了FDA内分泌及代谢药物专家咨询委员会16:0的支持率，不出意外的话，索马鲁肽上市在即[4]。
不少分析人士预测它未来十年内的销售峰值将超百亿，成为治疗2型糖尿病中最好的降糖药。
欧洲肠外肠内营养学会肠内营养指南
欧洲肠外肠内营养学会肠内营养指南欧洲肠外肠内营养学会（ESPEN）肠内营养指南于2006年刊登在《临床营养》（ClinicalNutrition）杂志上，为临床营养支持的应用提供了科学依据。
该指南采用苏格兰学院间指南协作网（SIGN）分级标准，A级推荐的内容为荟萃分析或随机对照研究的结果，B级推荐为描述研究、比较研究的结果，C级推荐为专家意见。
适当的营养支持可以帮助重症患者度过严重疾病导致的高分解状态，通过管饲的肠内营养（EN）是目前重症患者摄入营养物质的主要途径。
ESPEN指南对营养支持的应用、途径、和营养制剂配方做出了循证推荐。
Clin Nutr. 2006 Apr;25(2):210-23.ESPEN Guidelines on Enteral Nutrition: Intensive care.Kreymann KG, Berger MM, Deutz NE, Hiesmayr M, Jolliet P, Kazandjiev G, Nitenberg G, van den Berghe G, Wernerman J; DGEM (German Society for Nutritional Medicine), Ebner C, Hartl W, Heymann C, Spies C; ESPEN (European Society for Parenteral and Enteral Nutrition). Department of Intensive Care Medicine, University Hospital Eppendorf, Hamburg, Germany.Enteral nutrition (EN) via tube feeding is, today, the preferred way of feeding the critically ill patient and an important means of counteracting for the catabolic state induced by severe diseases. These guidelines are intended to give evidence-based recommendations for the use of EN in patients who have a complicated course during their ICU stay, focusing particularly on those who develop a severe inflammatory response, i.e. patients who have failure of at least one organ during their ICU stay. These guidelines were developed by an interdisciplinary expert group in accordance with officially accepted standards and are based on all relevant publications since 1985. They were discussed and accepted in a consensus conference. EN should be given to all ICU patients who are not expected to be taking a full oral diet within three days. It should have begun during the first 24h using a standard high-protein formula. During the acute and initial phases of critical illness an exogenous energy supply in excess of 20-25 kcal/kg BW/day should be avoided, whereas, during recovery, the aim should be to provide values of 25-30 total kcal/kg BW/day. Supplementary parenteral nutrition remains a reserve tool andshould be given only to those patients who do not reach their target nutrient intake on EN alone. There is no general indication for immune-modulating formulae in patients with severe illness or sepsis and an APACHE II Score >15. Glutamine should be supplemented in patients suffering from burns or trauma. 营养支持的应用所有3天内无法通过经口进食满足营养需求的重症患者需要接受肠内营养（C级推荐）。
国际上著名的从事药剂学研究的专家
Intra Oral Delivery (口腔内传递)直接由口腔黏膜吸收,瞬间进入血液循环,有效成分不流失。
Universities, Departments,FacultiesResearchersButler University College of Pharmacy and Health Sciences Health Sciences USA Associate Professor Nandita G. DasMain focus on her research facilities are about peformulation, biopharmaceutics, drug targeting, anticancer drug delivery.Purdue University School of Pharmacy and Pharmacal Sciences Department of Industrial and Physical Pharmacy (IPPH) USA Professor Kinam ParkControlled Drug Delivery, Glucose-Sensitive Hydrogels for Self-Regulated Insulin Delivery, Superporous Hydrogel Composites, Oral Vaccination using Hydrogel Microparticles, Fractal Analysis of Pharmaceutical Solid Materials.St. John's University School of Pharmacy and Allied Health ProfessionsUSA Professor Parshotam L. MadanControlled and targeted drug delivery systems; Bio-erodible polymers as drug delivery systemsThe University of Iowa College of Dentistry Department of Oral Pathology, Radiology, and Medicine USA Professor Christopher A. Squierpermeability of skin, and oral mucosa to exogenous substances, including alcohol and tobacco, and drug deliveryThe University of Iowa College of Pharmacy Department of Pharmaceutics USA Associate Professor Maureen D. DonovanMucosal drug delivery especially via the nasal, gastrointestinal and vaginal epithelia; and mechanisms of drug absorption and disposition.The University of Texas at San Antonio College of Engineering Department of Biomedical Engineering USA Professor Jeffrey Y. ThompsonDental restorative materials and implantsThe University of Utah Pharmaceutics & Pharmaceutical Chemistry USA Professor John W. MaugerDr. Maugner is mainly focused on dissolution testing and coating technology of orally administered drug products with bitter taste about which he is one of the inventors of a filed patent.University of Kentucky College of Pharmacy Pharmaceutical Sciences USA Professor Peter CrooksDr. Crooks is internationally known for his research work in drug discovery, delivery, and development, which includes drug design and synthesis, pharmacophore development, drug biotransformation studies, prodrug design, and medicinal plant natural product research. His research also focuses on preclinical drug development, including drug metabolism and pharmacokinetics in animal models, dosage form development, and drug delivery assessment using both conventional and non-conventional routes, and preformulation/formulation studies.Associate Professor Russell MumperDr. Mumper's main research areas are thin-films and mucoadhesive gels for (trans)mucosal delivery of drugs, microbicides, and mucosal vaccines, and nanotemplate engineering of nano-based detection devices and cell-specific nanoparticles for tumor and brain targeting, gene therapy and vaccines.West Virginia University School of Pharmacy Department of Basic Pharmaceutical Sciences USA Associate Professor Paula Jo Meyer StoutDr. Stout's research areas are composed of dispersed pharmaceutical systems, sterile product formulation DDS for dental diseases and coating of sustained release formulations.Monash University Victorian College of Pharmacy Department of Pharmaceutics Australia Professor Barrie C. FinninTransdermal Drug Delivery. Physicochemical Characterisation of Drug Candidates. Topical Drug Delivery. Drug uptake by the buccal mucosaProfessor Barry L. ReedTransdermal Drug Delivery. Topical Drug Delivery. Formulation of Dental Pharmaceuticals.University of Gent Faculty of Pharmaceutical Sciences Department of Pharmaceutics Belgium Professor Chris Vervaet-Extrusion/spheronisation - Bioadhesion - Controlled release based on hot stage extrusion technology - Freeze-drying - Tabletting and - GranulationPh.D. Els AdriaensMucosal drug delivery (Vaginal and ocular) Nasal BioadhesionUniversity of Gent Faculty of Pharmaceutical SciencesLaboratory of Pharmaceutical Technology Belgium Professor Jean Paul Remonbioadhesive carriers, mucosal delivery, Ocular bioerodible minitablets, Compaction of enteric-coated pellets; matrix-in-cylinder system for sustained drug delivery; formulation of solid dosage forms; In-line monitoring of a pharmaceutical blending process using FT-Raman spectroscopy; hot-melt extruded mini-matricesDanish University of Pharmaceutical Sciences Department of Pharmaceutics Denmark Associate Professor Jette JacobsenLow soluble drugs ?in vitro lymphatic absorption Drug delivery to the oral cavity ?in vitro models (cell culture, diffusion chamber) for permeatbility and toxicity of drugs, in vivo human perfusion model, different formulation approaces, e.g. iontophoresis.。
美国食品药品监督管理局对可吸收钙盐骨填充材料的监管案例分析与启示
196 ZHONGGUOYIXUEZHUANGBEI学术论著*基金项目：国家重点研发计划(2018YFB1105600)“血管化仿生关节多细胞精准3D打印技术与装备的开发及应用”①国家药品监督管理局医疗器械技术审评中心 北京 100081②国家药品监督管理局医疗器械技术审评检查大湾区分中心 广东 深圳 518045*通信作者：**************.cn作者简介：程玮璐，女，(1987- )，博士，高级工程师，从事医疗器械临床评价技术审评研究工作。
[文章编号] 1672-8270(2023)10-0196-05 [中图分类号] R197.39 [文献标识码] ACase analysis and inspiration of U.S FDA supervision on the absorbable calcium salts of bone filling materials/CHENG Wei-lu, ZHANG Yi-dan, LIU Ying-hui, et al//China Medical Equipment,2023,20(10):196-200.[Abstract] Objective: T o explore the supervisory situation of Food and Drug Administration (FDA) of United States of America for the absorbable calcium salts of bone filling materials, so as to provide references for the similar products that would be put on the domestic and international markets. Methods: The research contents of bench test (in vitro) and animal test (in vivo) before the absorbable calcium salts of bone filling materials were put on the markets were sorted out through retrieved the market situation of the absorbable calcium salts of bone filling materials in FDA, and gathered and arranged the guideline of the relevant techniques of that. And then, the evaluation path and the launching information of relevant products of FDA for the launch of the absorbable calcium salts of bone filling materials were further analyzed. Results: In the launching guideline of the absorbable calcium salts of bone filling materials, FDA clearly required the enterprises of bone filling materials should conduct bench test and animal test before the bone filling materials were put on the markets. For routine bone filling materials, the substantial equivalence path could be selected to carry out pre-market evaluations of products. Conclusion: The pre-market research content and the analysis of launching information of the enumerated relevant products of the absorbable calcium salts of bone filling materials of FDA can provide references for the launch of similar products at home and abroad.[Key words] Bone filling material; Food and drug administration (FDA); Pre-market research; Case study, Medical devices supervision and administration[First-author's address] Center for Medical Device Evaluation, National Medical Products Administration, Beijing 1000812, China.[摘要] 目的：分析美国食品药品监督管理局(FDA)对可吸收钙盐骨填充材料监管情况，探究类似产品在我国境内外上市的参考借鉴。
富血小板纤维蛋白联合Bio-Oss_骨粉修复颌骨囊肿术后骨缺损的疗效
[收稿日期]2021-08-25 [修回日期]2022-03-08[基金项目]安徽省马鞍山市科技计划项目(YL⁃2019⁃02)[作者简介]宁 晔(1989-),男,硕士研究生,主治医师.[通信作者]唐丽宇,主任医师.E⁃mail:tly1965@[文章编号]1000⁃2200(2024)02⁃0187⁃05㊃临床医学㊃富血小板纤维蛋白联合Bio⁃Oss 骨粉修复颌骨囊肿术后骨缺损的疗效宁 晔,唐丽宇,龚飞飞,庄劭玉,夏华宽(安徽省马鞍山市人民医院口腔科,243000)[摘要]目的:观察使用富血小板纤维蛋白(platelet⁃rich fibrin,PRF)联合Bio⁃Oss 骨粉修复颌骨囊肿术后骨缺损的临床疗效㊂方法:选取颌骨囊肿术后存在一定大小范围的骨缺损病人共36例作为研究对象,随机分为2组,各18例㊂对照组病人单纯使用Bio⁃Oss 充填修复骨缺损;观察组病人使用PRF 联合Bio⁃Oss 充填颌骨囊肿造成的骨缺损空腔㊂所有病人术后分别于3㊁6㊁12个月进行定期随访观察,通过CBCT 影像学检查测量骨密度值评估临床疗效㊂结果:观察组颌骨囊肿术后伤口愈合良好,对照组有1例术后7d 创口出现轻度糜烂红肿,未见充填材料排异反应㊂影像学检查显示观察组较对照组病人颌骨缺损空腔内的充填材料随着时间推移与新生骨及周围骨组织生长良好,能够达到临床满意的骨组织修复效果㊂观察组术后3㊁6㊁12个月骨缺损区骨密度均高于对照组,差异均有统计学意义(P <0.05~P <0.01)㊂结论:PRF 联合Bio⁃Oss 骨粉可有效提高颌骨囊肿术后骨缺损的成骨疗效㊂[关键词]颌骨囊肿;富血小板纤维蛋白;Bio⁃Oss 骨粉;骨缺损[中图法分类号]R 782 [文献标志码]A DOI :10.13898/ki.issn.1000⁃2200.2024.02.010Effects of platelet⁃rich fibrin combinedwith Bio⁃Oss bone substitute in the repair of postoperative bone defect of jaw cystNING Ye,TANG Liyu,GONG Feifei,ZHUANG Shaoyu,XIA Huakuan(Department of Stomatology ,The People′s Hospital of Maanshan ,Maanshan Anhui 243000,China )[Abstract ]Objective :To observe the clinical efficacy of platelet⁃rich fibrin(PRF)combined with Bio⁃Oss bone substitute in the repair of postoperative bone defect of jaw cyst.Methods :A total of 36patients with bone defects in a certain range after maxillary cyst surgery were randomly divided into the control group and observation group(18cases in each group).The control group was treated with Bio⁃Oss filling to repair bone defects,and the observation group was treated with PRF combined with Bio⁃Oss filling to repair the cavity of bone defect caused by jaw cyst.All patients were regularly followed up for 3,6and 12months after surgery,and the CBCT imaging was used to measure bone mineral density to evaluate the clinical efficacy.Results :The wounds of jawbone cyst in the observation group healed well after surgery,1case with mild erosion and redness in the control group was identified after 7days of surgery,and no rejection reaction of filling material was be observed.The results of imaging examination showed that compared with the control group,the filling materials in the cavity of jaw defect in the observation group grew well with the new bone and surrounding bone tissue over time,and the bone tissue repair effect could achieve clinical satisfactory.The bone mineral density in observation group was higher than that in control group at 3,6and 12months after surgery(P <0.05to P <0.01).Conclusions :The PRF combined with Bio⁃Oss bonesubstitute can effectively promote the osteogenic effect of bone defect after maxillary cyst surgery.[Key words ]jaw cyst;platelet⁃rich fibrin;Bio⁃Oss bone substitute;bone defect 颌骨囊肿是临床上比较常见的造成颌骨缺损的疾病,手术摘除颌骨囊肿后所遗留的骨性空腔往往使得创口延期愈合或出现继发性感染[1]㊂颌骨缺损修复多采用囊腔植骨术和生物材料置入术,但是植骨术的骨来源大多为自体骨,需要开辟第二术区,给病人造成额外痛苦,生物材料置入也会存在一定的排异反应和感染风险[2]㊂近年来,我科使用富血小板纤维蛋白(platelet⁃rich fibrin,PRF)联合Bio⁃Oss 骨粉修复颌骨囊肿术后骨缺损取得了良好的临床疗效,现作报道㊂1 资料与方法1.1 病例选取 选取2019年11月至2020年8月于马鞍山市人民医院口腔科收住的颌骨囊肿术后存在一定范围的骨缺损病人共36例,随机分为2组,每组18例㊂其中观察组男11例,女7例,平均年龄35.24岁;对照组男13例,女5例,平均年龄37.13岁㊂所有病人的治疗过程符合‘赫尔辛基宣言“的要求,并得到了马鞍山市人民医院伦理委员会的批准㊂术前均告知病人对所接受的治疗㊁预后及可能出现的并发症情况,病人知情同意并签字为据㊂纳入标准:(1)年龄≥18周岁,无不良烟酒嗜好,口腔卫生较好,依从性强;(2)颌骨囊肿大小3.0cm×2.0cm×1.0cm ~5.0cm×4.0cm×3.0cm,囊肿摘除后呈箱状骨缺损㊂排除标准:(1)患有糖尿病㊁骨质疏松等影响骨愈合的全身系统性疾病;(2)颌骨囊肿摘除后呈节段性缺损严重,必须进行自体骨移植,钛板坚强内固定;(3)因自身血液质量不佳,无法制备出足量的PRF㊂1.2 材料及器械 Bio⁃Oss骨粉(Geistlich Biomaterials,瑞士);海奥生物胶原修复膜(烟台正海生物技术有限公司,中国);Trausim血液离心机及特定配套的采血管㊁搅拌器及压膜成形器等(江苏创英医疗器械有限公司,中国)㊂1.3 手术过程 1.3.1 术前准备 拍摄CBCT测量评估颌骨囊肿大小范围,满足纳入标准的病人予以手术知情告知㊂术前30min静脉滴注 头孢呋辛钠”1.5g,行预防性抗感染治疗㊂1.3.2 PRF的制备 根据术前囊肿大小范围,评估使用不抗凝真空负压采血管的数目并采集病人适量肘部静脉血后迅速放入Trausim血液离心机中,以3000r/min的速度离心14min㊂离心后可见采血管中血液由上至下分为3层:血清层㊁PRF层及红细胞层㊂打开采血管将血清层倒去,用镊子轻轻夹取黄色胶冻状的PRF置管外,将PRF放入压膜成形器中压制成PRF膜备用(见图1)㊂1.3.3 手术方法 常规消毒铺巾,局麻下术区采用角形或梯形切口,切开㊁翻瓣㊁去骨,充分暴露囊腔并完整摘除囊肿后,酌情拔除囊肿涉及无法保留的病灶牙㊂仔细搔刮根尖周围及囊腔骨壁,修整骨创缘后用2%碘酊烧灼骨腔,0.9%氯化钠溶液彻底冲洗㊂观察组病人将一部分PRF膜剪碎成颗粒状与Bio⁃Oss骨粉混合搅拌均匀后填入囊肿术后骨缺损空腔内,取PRF膜及海奥生物胶原膜各一份,双层覆盖于骨缺损创面;对照组单纯填入Bio⁃Oss骨粉,覆盖生物胶原膜㊂2组病人均对位严密缝合组织瓣,关闭创口㊂1.4 观察评估 所有病人术后分别于3㊁6㊁12个月进行定期随访观察㊂临床大体观察术区软组织愈合情况,拍摄CBCT影像学观察骨缺损修复情况,通过测量骨缺损区骨密度值,判断2组病人的骨修复情况(见图2~3)㊂1.5 统计学方法 采用独立样本t检验㊂2 结果 术后2组病人随访观察3~12个月㊂其中观察组病人术后7d创口均达到Ⅰ期愈合,CBCT影像学观察病人骨缺损空腔内的充填材料随着时间推移与新生骨及周围骨组织生长良好,可见植骨区与周围正常骨组织的界限和密度逐渐接近,颌骨囊肿术后骨缺损大小范围较术前明显缩小㊂对照组存在1例病人术后7d创口轻度糜烂红肿,但未见充填材料排异溢露,经积极抗感染治疗5d后好转,CBCT影像学观察相比较,术前2组病人骨缺损区骨密度值均较低,差异无统计学意义(P>0.05);观察组术后3㊁6㊁12个月骨缺损区骨密度均高于对照组,差异均有统计学意义(P<0.05~P<0.01)(见表1)㊂表1 2组病人骨缺损区骨密度平均值比较(x±s;Hu)分组术前术后3个月术后6个月术后12个月观察组115.74±22.74503.46±40.13587.82±31.83702.36±30.23对照组110.94±20.19405.24±29.72461.03±28.87547.36±35.87t0.678.3411.6314.02P>0.05<0.05<0.05<0.013 讨论 牙源性颌骨囊肿非常多见于青壮年颌骨的任何牙位㊂无论是好发于前牙区的根尖周囊肿,还是好发于后牙区的含牙囊肿或始基囊肿,手术摘除囊肿并拔除病灶牙后所遗留一定大小范围的骨缺损往往难以自行愈合,导致牙槽嵴宽度和高度得不到有效恢复,从而造成颌骨骨量不足影响后期义齿的修复[3]㊂目前,临床上多采用自体骨移植或人工骨充填的方法来修复颌骨囊肿术后造成一定大小范围的中㊁大型骨缺损[4]㊂尤其是近年来,随着种植义齿修复技术的成熟和推广,越来越多的颌骨囊肿术后病人需求种植义齿修复来提高自身的生活质量㊂为了促使病人能较快地修复颌骨缺损满足后期种植义齿修复,同时又能避免病人开辟第二术区的痛苦,本研究针对颌骨囊肿术后病人均采用国内外一致好评的Bio⁃Oss人工骨粉作为修复材料㊂大量研究已表明Bio⁃Oss骨粉晶体结构与人体骨的无机成分相似,材料颗粒具有多孔隙,溶解度高,表面性能大,无细胞毒性,生物相容性好的特性[5]㊂Bio⁃Oss修复骨缺损的机制在于骨粉颗粒多孔隙结构为成骨细胞提供附着支架,并在其表面沉积,随着骨形成中钙㊁磷离子缓慢释放,骨粉颗粒逐渐吸收,新骨逐渐钙化形成㊂虽然Bio⁃Oss在骨缺损处作为组织工程的支架优势明显,但是该材料只具备骨传导作用,缺乏较强的骨诱导和抗感染能力[6],故制备出一种成骨性能优良的Bio⁃Oss复合支架材料就显得尤为重要㊂研究[7]发现,在颌骨缺损修复中使用自体血小板浓缩物能够提高骨诱导能力,防止创口感染发生从而加快成骨效果形成㊂PRF制备工艺简单,血液提取后不需要额外添加凝血酶和抗凝剂就可以避免发生交叉感染和排异反应的风险[8-9]㊂另外PRF还富含大量生长因子㊁外周血干细胞及免疫细胞,在炎症调节和抗感染方面都发挥了较好的效果[10]㊂本研究将PRF和Bio⁃Oss制作成复合材料就是要发挥各自优势,促进范围较大骨缺损的成骨效果㊂本研究观察组病人术后3个月时已有新骨形成,术后6个月时骨缺损区新生骨面积明显扩大,到术后12个月新生骨组织密度进一步增强,与周围正常骨组织界限趋于模糊,有骨小梁生成㊂这也再次表明Bio⁃Oss所具有的三维多孔结构,有利于成骨细胞蔓延生长和毛细血管彼此连通,可以促进成骨细胞黏附和功能代谢[11]㊂同时,PRF中富含的血小板被激活后释放出转移性生长因子㊁表皮生长因子和血管内皮细胞生长因子等多种生长因子,一方面对成骨细胞的分化和增殖起着促进作用,另一方面抑制破骨细胞生成功能㊂这些生长因子之间具有协同效应并与骨形成蛋白相互作用,共同维持着组织环境的平衡,对骨缺损的成骨再生也起着十分重要的作用[12]㊂我们在临床观察发现,观察组病人的骨密度值明显比对照组高,经统计学数据分析也证实了观察组使用PRF联合Bio⁃Oss具有良好的促进骨修复效果㊂可见,随着Bio⁃Oss表面成骨细胞的聚集和PRF中大量生长因子浓度的提高,促进了成骨细胞增殖㊁矿化,从而形成有效的骨整合㊂本研究在Bio⁃Oss中加入PRF后,使得Bio⁃Oss材料既具有骨传导性,又具有骨诱导潜能,能够明显提高成骨效果㊂另外,在颌骨缺损空腔内仅仅充填复合人工骨材料是难以达到满意的成骨效果,良好的屏障膜覆盖,无张力严密缝合也至关重要㊂本研究中使用的口腔修复膜为一种牛皮处理制备的异种脱细胞真皮基质,可诱导成骨细胞贴附,参与生物降解过程,可阻挡牙龈上皮细胞进入骨缺损空腔内,维持成骨细胞生长的三维空间结构,创造出良好的骨再生环境[13]㊂研究中还充分利用PRF膜中的纤维蛋白属于血管化天然诱导物,有利于营养成分及氧气输入至骨髓干细胞周围,促进分化为成骨细胞的特性[14]㊂本研究中骨缺损空腔类型多为箱状,四周均有骨壁且唯一的开放创面覆盖屏障膜,能够有效防止咀嚼运动时骨充填材料向四周外溢㊂我们将PRF 凝胶压制成膜,发现PRF膜具有良好的抗剪切性和拉伸强度㊂为促进骨再生,防止创面感染,所有病人均使用PRF膜覆盖于人工骨材料表面㊂BORIE 等[15]研究就发现在骨增量术中使用PRF膜能够促进口腔软硬组织愈合,减少术后肿痛和感染㊂本研究对照组病人中有1例出现术区创面轻度红肿糜烂,经病情回溯发现为病人术后进食硬物致创面部分缝线疏松滑脱,再加上口腔卫生保持不佳所致,若创面覆盖PRF膜一定程度上就会减少创面感染的概率㊂综上所述,PRF联合Bio⁃Oss对颌骨囊肿术后骨缺损的修复具有一定的成骨效果,值得在临床上推广及应用㊂但在临床观察中,我们对如何选取合适的PRF与Bio⁃Oss的混合比例尚无统一标准,不同年龄段病人的自体血液和颌骨质量也有所差别,这些因素都会影响颌骨缺损修复的作用和疗效㊂因此PRF联合Bio⁃Oss修复颌骨囊肿术后骨缺损的稳定性还有待于长时间㊁大样本观察研究㊂[参考文献][1] ZHANG ZY.Oral and maxillofacial surgery[M].7th ed.Beijing:People′s Medical Publishing House,2012:177.[2] ZHOU J,DU RH.Assessment on the treatments for cyst of thejaws[J].J Oral Maxillofac Surg,2012,22(4):229. [3] CHIAPASCO M,ROSSI A,MOTTA JJ,et al.Spontaneous boneregeneration after enucleation of large mandibular cysts:aradiographic computed analysis of27consecutive cases[J].JOral Maxillofac Surg,2000,58(9):942.[4] AKRAM M,FAROOQ FM,SHAHZAD ML,et al.A comparison oftreating unicameral bone cyst using steroids and percutaneousautologous bone marrow aspiration injection[J].J Pak MedAssoc,2015,65(11Suppl3):S156.[5] 王国世,李韶伟,蔡露.牙种植采用引导骨再生术Bio⁃oss吸收的定量分析[J].上海口腔医学,2012,21(3):317. [6] SIVOLELLA S,BRESSAN E,SALATA LA,et al.Deproteinizedbovine bone mineral particles and osseointegration of implantswithout primary bone contact:an experimental study in dogs[J].Clin Oral Implants Res,2014,25(3):296.[7] AMIT A.Evolution current status and advances in application ofplatelet concentrate in periodontics and implantology?[J].World J Clin Cases,2017(5):159.[8] DOHAN DM,CHOUKROUN J,DISS A,et al.Platelet⁃rich fibrin(PRF):a second⁃generation platelet concentrate.PartⅢ:leucocyte activation:a new feature for platelet concentrates[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2006,101(3):e51.[9] 方冬冬,后军,杨全全,等.富血小板纤维蛋白复合骨诱导在颌骨缺损中的应用疗效[J].安徽医学,2016,37(7):868. [10] 周延民,付丽.富血小板纤维蛋白在口腔软硬组织再生中的作用 回顾与展望[J].口腔医学,2018,38(11):961. [11] SHAH R,THOMAS R,MEHTA DS.An update on the protocolsand biologic actions of platelet rich fibrin in dentistry[J].Eur JProsthodont Restor Dent,2017,25(2):64.[12] AZITA T,HOSSEIN B,FEREYDOUN P,et al.The effect ofautologous leukocyte platelet rich fibrin on the rate of orthodontictooth movement:a prospective randomized clinical trial[J].WorldJ Clin Cases,2017(5):159.[13] DEYHIMI P,RAZAVI SM,SHAHNASERI S,et al.Rare andextensive malignant melanoma of the oral cavity:report of twocases[J].J Dent(Shiraz),2017,18(3):227.。
沼泽红假单胞菌应用的研究进展
六溴环十二烷（ ＨＢＣＤ） 等污染物。 沼泽红假单胞菌 ５１ＡＴＡ
红假单胞菌 ＰＳＢ１ 对废水中氨氮的降解率可达 ９９％ ［２８］ 。 氯
代苯甲酸（ ＣＢＡｓ） 是一种由氯化物分解而产生的环境污染
物。 沼泽红假单胞菌 ＲＣＢ１００ 通过将 ３－氯苯甲酸（３－ＣＢＡ）
转化为 ３－氯苯甲酰辅酶 Ａ 和将其还原脱卤生成苯甲酰辅酶
Ａｂｓｔｒａｃｔ Ｒｈｏｄｏｐｓｅｕｄｏｍｏｎａｓ ｐａｌｕｓｔｒｉｓ ｉｓ ｗｉｄｅｌｙ ｄｉｓｔｒｉｂｕｔｅｄ ｉｎ ｎａｔｕｒｅ． Ｂｅｃａｕｓｅ ｏｆ ｉｔｓ ｕｎｉｑｕｅ ｐｈｙｓｉｏｌｏｇｉｃａｌ ｃｈａｒａｃｔｅｒｉｓｔｉｃｓ， ｉｔ ｈａｓ ｂｅｅｎ ａｐｐｌｉｅｄ
ｉｎ ｍａｎｙ ｆｉｅｌｄｓ． Ｉｎ ｔｈｉｓ ｐａｐｅｒ， ｔｈｅ ａｐｐｌｉｃａｔｉｏｎ ｏｆ Ｒｈｏｄｏｐｓｅｕｄｏｍｏｎａｓ ｐａｌｕｓｔｒｉｓ ｉｎ ａｇｒｉｃｕｌｔｕｒｅ， ａｑｕａｃｕｌｔｕｒｅ， ｅｎｖｉｒｏｎｍｅｎｔａｌ ｔｒｅａｔｍｅｎｔ ａｎｄ ｃｈｅｍｉｃａｌ
等方面起重要的作用。
属，是研究光合磷酸化、固氮调节、产氢以及厌氧降解芳香族
水稻、烟草［５］ 和白菜等植物体内，能够释放 ＩＡＡ 和 ５－ＡＬＡ 等
氧的光合细菌，为紫色非硫细菌，属于红螺菌科，红假单胞菌
化合物的模式生物。 沼泽红假单胞菌具有多种营养类型，如
进行厌氧光能自养、厌氧光能异养和好氧异养生长，它可以
生长［２６］ 。
３ 环境修复方面的应用
沼泽红假单胞菌具有较高的氨氮去除能力，并吸附、降
叶绿素含量，提高了过氧化氢酶（ ＣＡＴ）、抗坏血酸过氧化物
解废水中的污染物，包括染料、氯代苯甲酸和 １，２，５，６，９，１０－
的抗氧化活性。 沼泽红假单胞菌 ＴＮ１１４ 可以通过分泌 ＥＰＳ，
一种黄嘌呤氧化酶的冻干保护剂及其应用[发明专利]
![一种黄嘌呤氧化酶的冻干保护剂及其应用[发明专利]](https://img.taocdn.com/s3/m/88100e14f90f76c660371aa9.png)
专利名称：一种黄嘌呤氧化酶的冻干保护剂及其应用专利类型：发明专利
发明人：汪海霞,杨武剑,陆婷,郑颖
申请号：CN201310180574.7
申请日：20130515
公开号：CN103224924A
公开日：
20130731
专利内容由知识产权出版社提供
摘要：本发明属于酶的保存技术领域，具体涉及一种黄嘌呤氧化酶的冻干保护剂及其应用。
本发明提供一种黄嘌呤氧化酶的冻干保护剂，每100ml缓冲液中，包含如下组分：海藻糖0.5-10g；L-组氨酸0.1-5g；铁卟啉0.01-0.1g。
本发明的冻干保护剂的使用效果表明可使黄嘌呤氧化酶37℃下7天后活性残留90%以上，-20℃2年后活性残留90%。
另外，本发明的制剂配方与现有专利中的配方相比，具有更好的加速稳定性。
申请人：上海蓝园生物工程有限公司
地址：201203 上海市浦东新区张江高科技园区哈雷路1011号102室
国籍：CN
代理机构：上海光华专利事务所
更多信息请下载全文后查看。
螺旋霉素的生产工艺流程
螺旋霉素的生产工艺流程英文回答：Lincosamides, a class of antibiotics, are produced by fermentation using certain strains of Streptomyces bacteria. One of the most well-known lincosamides is clindamycin,also known as spiramycin. The production process of spiramycin involves several steps.Firstly, a suitable strain of Streptomyces bacteria is selected and cultured in a nutrient-rich medium. This medium typically contains a carbon source, such as glucoseor molasses, nitrogen sources like soybean meal or corn steep liquor, and other essential minerals and vitamins.The bacteria are allowed to grow and multiply in this medium under controlled conditions of temperature, pH, and oxygen supply.Once the bacteria have reached the desired growth phase, the fermentation broth is harvested. This broth containsthe desired antibiotic compound, along with other metabolites produced by the bacteria. The broth is then subjected to a series of separation and purification steps to isolate the spiramycin.One common method for purification is solvent extraction. Organic solvents, such as ethyl acetate or butanol, are added to the fermentation broth to extract the spiramycin. The solvent phase is then separated from the aqueous phase, and the solvent is evaporated to obtain a crude extract of spiramycin.The crude extract is further purified using techniques like chromatography or crystallization. Chromatography involves passing the crude extract through a column packed with a stationary phase, which separates the different components based on their affinity to the stationary phase. Crystallization involves cooling the crude extract to induce the formation of pure spiramycin crystals, which can be separated from the mother liquor.The purified spiramycin is then dried and milled into afine powder. It is then formulated into various dosage forms, such as tablets or capsules, for oral administration. The final product undergoes quality control testing to ensure its potency, purity, and safety before it is packaged and distributed.中文回答：螺旋霉素是一类抗生素，通过利用某些链霉菌的菌株进行发酵生产。
蜂胶乙醇提取物对小鼠心肌SOD，CAT含量的影响
蜂胶乙醇提取物对小鼠心肌SOD，CAT含量的影响
韩银淑;韩桂萍;于英君
【期刊名称】《中华医学写作杂志》
【年(卷),期】2001(008)012
【摘要】通过观察蜂胶乙醇提取物(EEP)对小鼠心肌SOD，CAT含量的影响，探讨蜂胶的抗氧化作用。
结果表明，给予EEP灌胃的小鼠心肌SOD，CAT含量明显高于空白对照组(P<0．01)。
其中EEP中、高两个剂量组的抗氧化作用尤为显著。
【总页数】2页(P1360-1361)
【作者】韩银淑;韩桂萍;于英君
【作者单位】黑龙江省鸡西煤炭医学高等专科学校，158100;黑龙江中医药大学生化教研室
【正文语种】中文
【中图分类】R-332
【相关文献】
1.蜂胶乙醇提取物对小鼠心肌DNA甲基化的影响 [J], 韩银淑
2.蜂胶乙醇提取物对小鼠NO及Na+-K+ATPase和脂质过氧化作用的影响 [J], 郭丽新;齐彦;于赫;于英君;张彦华
3.蜂胶对衰老小鼠脑组织SOD及MDA含量影响的实验研究 [J], 张春蕾;于英君
4.蜂胶乙醇提取物对小鼠心脏蛋白质与核酸合成代谢的影响 [J], 郭艳萍;＊t-雪松;张悦
5.蜂胶胶囊对小鼠的毒性及对体内SOD酶、MDA含量的影响研究 [J], 梁晓芸;聂木海;诸茂盛
因版权原因，仅展示原文概要，查看原文内容请购买。
明治点心公司销售加入酪蛋白磷酸肽的保健食品
明治点心公司销售加入酪蛋白磷酸肽的保健食品
孙国凤
【期刊名称】《生物技术通报》
【年(卷),期】1989(000)007
【摘要】日本明治点心公司(明治制果)1988年2月宣布商品化了加入酪蛋白一磷酸肽(CPP)的钙片。
CPP 是能对乳蛋白成分的酪蛋白进行有限分解的肽,它是在蛋白分解酶胰蛋白酶的作用下生成的。
已知有来自酪蛋白的CPP(37个氨基酸)和来自β酪蛋白的βCPP(25个氨基酸)两种。
已确认具有在小肠下部促进吸收钙和秩的效果(参阅本
【总页数】1页(P28-28)
【作者】孙国凤
【作者单位】
【正文语种】中文
【中图分类】Q81
【相关文献】
1.福禄克公司医疗设备检测部产品加入福禄克中国的市场和销售体系 [J], 美国福禄克公司北京办事处
2.保健食品欺诈浙江10部门联合出击严打食品保健食品销售欺诈 [J], 无;
3.明治点心公司发售食物纤维饮料“低纤维饮料” [J], 孙国凤
4.日狮子公司将销售加入“溶化牙石”的酶的新牙膏 [J], 孙国凤
5.HPLC法测定保健食品中酪蛋白磷酸肽 [J], 田随安;张向兵;李永利
因版权原因，仅展示原文概要，查看原文内容请购买。
分析细菌溶解产物胶囊辅助治疗反复呼吸道感染患儿的疗效
分析细菌溶解产物胶囊辅助治疗反复呼吸道感染患儿的疗效发布时间：2023-02-22T03:39:16.301Z 来源：《中国结合医学杂志》2023年1期作者：陈钦陈鲁闽胡婷婷[导读] 阐述细菌溶解产物胶囊辅助治疗反复呼吸道感染患儿的疗效。
陈钦，陈鲁闽通讯作者，胡婷婷福建省儿童医院(上海儿童医学中心福建医院) 福建医科大学妇儿临床医学院摘要：目的阐述细菌溶解产物胶囊辅助治疗反复呼吸道感染患儿的疗效。
方法选取2020年1月-2022年4月我院收治的反复呼吸道感染患儿100例，根据不同的治疗方法将其分为对照组和研究组各50例，其中对照组进行对症治疗，而研究组则进行细菌溶解产物胶囊辅助治疗，进而通过观察患儿间疾病状况、心理状况以及生活质量，以此分析治疗方法的有效性。
结果研究组患儿症状消失时间、免疫指标、炎症因子水平、不良反应发生率明显低于对照组（P<0.05）。
同时研究组患儿生活质量、SAS评分和SDS评分以及治疗满意度和睡眠质量明显优于对照组（P<0.05）。
结论细菌溶解产物胶囊具有良好的实施效果，其能够对反复呼吸道感染的患儿产生积极的影响，不仅可以使得患儿拥有良好的疾病恢复状况，同时亦可为患儿拥有良好生活质量提供巨大帮助，且安全性较高。
关键词：细菌溶解产物胶囊；辅助治疗；反复呼吸道感染；治疗效果Abstract: Objective To elucidate the efficacy of Bacterial lysates in the adjuvant treatment of children with recurrent respiratory tract infection. Methods From January 2020 to April 2022, 100 children with recurrent respiratory tract infection in our hospital were selected and divided into control group and research group according to different treatment methods, with 50 cases in each group. The control group received symptomatic treatment, while the research group received adjuvant treatment with Bacterial lysates. Furthermore, the effectiveness of the treatment was analyzed by observing the disease status, psychological status and quality of life among the children. Results Time of symptom resolution immune indexes, inflammatory factor levels and the incidence of adverse reactions in the study group were significantly lower than those in the control group (P<0.05). Meanwhile, the quality of life, SAS score and SDS score, treatment satisfaction and sleep quality of children in the study group were significantly better than those in the control group (P<0.05). Conclusion Bacterial lysates has a good implementation effect, it can have a positive impact on the children with recurrent respiratory tract infection, can not only make the children have a good recovery condition, but also provide great help for the children to have a good quality of life, and high safety.Key words: Bacterial lysates； Adjuvant therapy; Recurrent respiratory tract infection; Effect of treatment反复呼吸道感染（Recurrent Respiratory Tract Infection RRTI)属于常见疾病，其具有一定程度的传染性。